Bionano Genomics, Inc. entered into Agreement and Plan of Merger with Purigen Biosystems, Inc. valued at approximately $32.0 million in cash, with additional consideration of up to $32.0 million in cash (effective 2022-11-23).
“On November 23, 2022, Bionano Genomics, Inc., a Delaware corporation (the “Company”), Mazdan Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Purigen Biosystems, Inc., a Delaware corporation (“Purigen”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the securityholders’ representative (“Securityholders’ Representative”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which the Company agreed to acquire Purigen.”
Richard Shippy resigned as Chief Business Officer at Bionano Genomics, Inc..
“On November 14, 2022, Richard Shippy resigned from his position as Chief Business Officer of Bionano Genomics, Inc., effective immediately.”
Earnings Releases
Bionano Genomics, Inc. reported financial results for third quarter ended September 30, 2022.
“On November 3, 2022 , Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2022.”
Aleksandar Rajkovic was appointed as Class III Director at Bionano Genomics, Inc..
“the Board appointed Aleksandar Rajkovic, M.D., Ph.D. as a Class III director, effective as of such date”
Vincent J. Wong was appointed as Class I director at Bionano Genomics, Inc..
“On December 21, 2021, the Board appointed Vincent J. Wong as a Class I director, effective as of such date, to serve in such capacity until the Company’s 2022 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.